Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

The behavior-analytic origins of constraint-induced movement therapy: an example of behavioral neurorehabilitation.
Vitamin D status and the risk of multiple sclerosis: A systematic review and meta-analysis.
Dendritic cells and multiple sclerosis: disease, tolerance and therapy.
The Multiple Sclerosis Work Difficulties Questionnaire (MSWDQ): development of a shortened scale.
Advances in Antioxidative Therapy of Multiple Sclerosis.
Curcumin Serves as a Human Kv1.3 Blocker to Inhibit Effector Memory T Lymphocyte Activities.
Balò's concentric sclerosis: still to be considered as a variant of multiple sclerosis?
Immunomodulatory therapies delay disease progression in multiple sclerosis.
Cerebrospinal Fluid Flow Dynamics in Multiple Sclerosis Patients through Phase Contrast Magnetic Resonance Imaging.
Fingolimod Increases CD39-Expressing Regulatory T Cells in Multiple Sclerosis Patients.
[Cost of multiple sclerosis in France.]
Demyelination reduces brain parenchymal stiffness quantified in vivo by magnetic resonance elastography.
Uveitis as a prognostic factor in multiple sclerosis.
Complications of Immunosuppressive/Immunomodulatory Therapy in Neurological Diseases.
Central nervous system demyelinating diseases and recombinant hepatitis B vaccination: a critical systematic review of scientific production.
The phosphorylated prodrug FTY720 is a histone deacetylase inhibitor that reactivates ERα expression and enhances hormonal therapy for breast cancer.
Fingolimod in active multiple sclerosis: an impressive decrease in Gd-enhancing lesions.
Improved clinical behavior of established relapsing-remitting experimental autoimmune encephalomyelitis following treatment with endogenous opioids: Implications for the treatment of multiple sclerosis.
HMGB1 in Development and Diseases of the Central Nervous System.
Multiple sclerosis: Etiology, symptoms, incidence and prevalence, and implications for community living and employment.
Increased B cell and cytotoxic NK cell proportions and increased T cell responsiveness in blood of natalizumab-treated multiple sclerosis patients.
Treatment of a relapse-remitting model of multiple sclerosis with opioid growth factor.
Natalizumab in clinical practice: managing the risks, enjoying the benefits.
Long-Term Data of Efficacy, Safety and Tolerability in a Real Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients.
Current status of myelin replacement therapies in multiple sclerosis.

Pages